# OnCo record olverembatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olverembatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olverembatinib" ;
  schema:name "Olverembatinib"@en ;
  schema:alternateName "GZD824"@en ;
  schema:description "Olverembatinib is Ascentage Pharma's third-generation BCR-ABL inhibitor, approved in China in 2021 for chronic myeloid leukaemia carrying the T315I mutation, and now in global phase 3 trials against the established drugs; it was the one China-only approval OnCo found missing from the headline list."@en ;
  schema:url <https://onco.cc/drugs/olverembatinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Olverembatinib> ;
  schema:citation <https://clinicaltrials.gov/search?intr=HQP1351> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral third-generation BCR-ABL tyrosine kinase inhibitor" ;
  onco:approval "CN 2021: Chronic myeloid leukaemia (chronic or accelerated phase) with the T315I mutation after prior tyrosine kinase inhibitors" ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/cml-advanced-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:companies <https://onco.cc/companies/ascentage-pharma/> ;
  onco:trials <https://onco.cc/trials/nct06423911/>, <https://onco.cc/trials/nct06640361/>, <https://onco.cc/trials/nct06051409/>, <https://onco.cc/trials/nct04501120/> .